Cargando…

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma

Detalles Bibliográficos
Autores principales:	Funes, H Cortés, Lluch, A, Climent, M, López, JJ, Ojeda, B, Hornedo, J, Ciruelos, E, Baselga, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231908/ http://dx.doi.org/10.1186/bcr1228

Ejemplares similares

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

Solti, Zarathustra
por: Strauss, Richard, 1864-1949
Publicado: (1997)

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
por: Ayala de la Peña, Francisco, et al.
Publicado: (2023)

The role of Xeloda in metastasic breast cancer
por: Cortés-Funes, H
Publicado: (2005)

Adjuvant therapy after preoperative treatment for breast cancer
por: Ciruelos, E
Publicado: (2009)

Effect of 24 weeks of intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir
por: Díaz, L, et al.
Publicado: (2010)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Efficacy and safety of the administration of bevacizumab in combination with first-line chemotherapy for the treatment of advanced breast carcinoma: ATHENA MO19391 study results in Spanish patients
por: Ciruelos, EM, et al.
Publicado: (2009)

Management of solid and sub-solid lung nodules
por: Herold, Christian J
Publicado: (2014)

SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
por: Garcia-Saenz, Jose Angel, et al.
Publicado: (2023)

The EGF receptor family as targets for breast cancer therapy
por: Baselga, J
Publicado: (2000)

Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
por: Garcia-Saenz, Jose Angel, et al.
Publicado: (2023)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
por: Pernas, Sonia, et al.
Publicado: (2021)

Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
por: Nieto, Y
Publicado: (2005)

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab
por: Manso, L, et al.
Publicado: (2009)

Apoptotic chemotherapies
por: Pardee, AB, et al.
Publicado: (2005)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

The Trunk Appearance Perception Scale (TAPS): a new tool to evaluate subjective impression of trunk deformity in patients with idiopathic scoliosis
por: Sánchez Raya, J, et al.
Publicado: (2012)

Sonographic evaluation of solid breast nodules
por: Stavros, T
Publicado: (2004)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011)

P354 Mold infections in solid organ transplant recipients in indian setting
por: Enaganthi, Niveditha, et al.
Publicado: (2022)

Targeting the right chemotherapy for the right patient
por: Conte, PF, et al.
Publicado: (2005)

OA01.04. The effectiveness and cost effectiveness of acupressure for chemotherapy-related nausea
por: Hughes, J, et al.
Publicado: (2012)

Is surgical diagnostic excision always necessary for solid lesions with atypia?
por: Sharma, Nisha, et al.
Publicado: (2015)

Role of translational studies in optimizing palliative chemotherapy
por: Kramer, R
Publicado: (2005)

Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets
por: Bond, Simon, et al.
Publicado: (2013)

Unfavorable metabolic changes are accompanied by impaired myocardial function shortly after chemotherapy
por: Van Der Meer, RW, et al.
Publicado: (2013)

Gene expression profile-based predictors of response to chemotherapy
por: Pusztai, L
Publicado: (2005)

Primary chemotherapy for operable breast cancer: the NSABP experience
por: Bear, HD
Publicado: (2005)

Lobular carcinoma of the breast: outcome of 205 patients
por: Vega, E, et al.
Publicado: (2011)

Cellular immune responses and changes in VL after a Dendritic Cells (DC)-based therapeutic vaccine in cART treated chronic HIV-infected patients with CD4 T cells above 450/mm
por: García, F, et al.
Publicado: (2012)

MFD-simulation of surface coatings – an extension to solid/fluid molecular modelling models
por: Richter, Daniel S, et al.
Publicado: (2008)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

O050 The Dose and Timing Relationship between Caffeine and Subsequent Sleep
por: Gardiner, C, et al.
Publicado: (2023)

AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy
por: Nguyen, HQ, et al.
Publicado: (2009)

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
por: Baselga, J, et al.
Publicado: (2011)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Activation of the pyrin inflammasome through the RhoA signaling pathway in FMF and HIDS
por: Park, YH, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l0a0sc0igppessmlc78srpc95u